Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 519-532

  Fedida, David ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ACT trial; Antiarrhythmic drugs; Atrial fibrillation; CRAFT trial; hERG channels; IKur; Kv1.5; Late sodium current; Paroxysmal atrial fibrillation; Potassium channel; Sodium channel

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOFILIUM; DIGOXIN; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; METHOXAMINE; PLACEBO; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; RSD 1235; SODIUM CHANNEL; SODIUM CHLORIDE; SOTALOL; UNCLASSIFIED DRUG; VERNAKALANT;

AREA UNDER THE CURVE; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE DURATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE PACING; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; HYPOTENSION; LABORATORY TEST; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; QRS COMPLEX; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUS RHYTHM; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUGS, INVESTIGATIONAL; HEART ATRIA; HUMANS;

EID: 34147105609     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.519     Document Type: Review

References (95)

1. KANNEL WB, WOLF PA, BENJAMIN EJ, LEVY D: Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: populationbased estimates. Am. J. Cardiol. (1998) 82:2N-9N.
2. FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of the Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J. Am. Coll. Cardiol. (2001) 38:1231-1266.
3. WATTIGNEY WA, MENSAH GA, CROFT JB: Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 108:711-716.
4. FUSTER V, RYDEN LE, CANNOM DS et al.: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 114:e257-e354.
5. BHANDARI AK, ANDERSON JL, GILBERT EM et al.: Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am. Heart J. (1992) 124:381-386.
6. GO AS, HYLEK EM, PHILLIPS KA et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Styudy. JAMA (2001) 285:2370-2375.
7. ROCKSON SG, ALBERS GW: Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J. Am. Coll. Cardiol. (2004) 43:929-935.
8. WOLF PA, DAWBER TR, THOMAS HE Jr, KANNEL WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology (1978) 28:973-977.
9. KHAN IA: Atrial stunning: basics and clinical considerations. Int. J. Cardiol. (2003) 92:113-128.
10. MOE GK, RHEINBOLDT WC, ABILDSKOV JA: A computer model of atrial fibrillation. Am. Heart J. (1964) 67:200-220.
11. RENSMA PL, ALLESSIE MA, LAMMERS WJ, BONKE FI, SCHALIJ MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ. Res. (1988) 62:395-410.
12. LAMMERS WJ, ALLESSIE MA, BONKE FI: Reentrant and focal arrhythmias in low potassium in isolated rabbit atrium. Am. J. Physiol. (1988) 255:H1359-H1369.
13. NATTEL S: New ideas about atrial fibrillation 50 years on. Nature (2002) 415:219-226.
14. BENJAMIN EJ, LEVY D, VAZIRI SM, D'AGOSTINO RB, BELANGER AJ, WOLF PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840-844.
15. ALLESSIE MA, BOYDEN PA, CAMM AJ et al.: Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 103:769-777.
16. ORAL H, KNIGHT BP, TADA H et al.: Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation (2002) 105:1077-1081.
17. LEUNG JM, BELLOWS WH, SCHILLER NB: Impairment of left atrial function predicts post-operative atrial fibrillation after coronary artery bypass graft surgery. Eur. Heart J. (2004) 25:1836-1844.
18. VERBEET T: [Resistant atrial fibrillation: how far does one go in its treatment?]. Rev. Med. Brux. (1999) 20:A237-A244.
19. WIJFFELS MC, CRIJNS HJ: Rate versus rhythm control in atrial fibrillation. Cardiol. Clin. (2004) 22:63-69.
20. PRYSTOWSKY EN: Assessment of rhythm and rate control in patients with atrial fibrillation. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl.2):S7-S10.
21. ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. N. Engl. J. Med. (2000) 342:913-920.
22. LEE SH, YU WC, CHENG JJ et al.: Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation (2000) 101:200-206.
23. VAN NOORD T, VAN GELDER IC, TIELEMAN RG et al.: VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. (2001) 12:766-769.
24. CORLEY SD, EPSTEIN AE, DI MARCO JP et al.: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 109:1509-1513.
25. HAGENS VE, RANCHOR AV, VAN SONDEREN E et al.: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J. Am. Coll. Cardiol. (2004) 43:241-247.
26. NATTEL S, OPIE LH: Controversies in atrial fibrillation. Lancet (2006) 367:262-272.
27. MITTAL S, STEIN KM, MARKOWITZ SM, IWAI S, GUTTIGOLI A, LERMAN BB: An update on electrical cardioversion of atrial fibrillation. Cardiol. Electrophysiol. Rev. (2003) 7:285-289.
28. BORIANI G, BIFFI M, DIEMBERGER I, MARTIGNANI C, BRANZI A: Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs (2003) 63:1489-1509.
29. ROY D, ROWE BH, STIELL IG et al.: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. (2004) 44:2355-2361.
30. BORIANI G, DIEMBERGER I, BIFFI M, MARTIGNANI C, BRANZI A: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs (2004) 64:2741-2762.
31. BORIANI G, MARTIGNANI C, BIFFI M, CAPUCCI A, BRANZI A: Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs (2002) 62:415-423.
32. DELL'ORFANO JT, PATEL H, WOLBRETTE DL, LUCK JC, NACCARELLI GV: Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am. J. Cardiol. (1999) 83:788-790 (A10).
33. NATTEL S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc. Res. (1998) 37:567-577.
34. WIJFFELS MC, DORLAND R, MAST F, ALLESSIE MA: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, fiecainide, and D-sotalol. Circulation (2000) 102:260-267.
35. NATTEL S, HADJIS T, TALAJIC M: The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities, and therapeutic considerations. Drugs (1994) 48:345-371.
36. FLAKER GC, BLACKSHEAR JL, MCBRIDE R, KRONMAL RA, HALPERIN JL, HART RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. (1992) 20:527-532.
37. MORGANROTH J: Risk factors for the development of proarrhythmic events. Am. J. Cardiol. (1987) 59:32E-37E.
38. KNELLER J, KALIFA J, ZOU R et al.: Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ. Res. (2005) 96:e35-e47.
39. ALLESSIE MA, BONKE FI, SCHOPMAN FJ: Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The 'leading circle' concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ. Res. (1977) 41:9-18.
40. MOE GK: A conceptual model of atrial fibrillation. J. Electrocardiol. (1968) 1:145-146.
41. KIRCHHOF C, WIJFFELS M, BRUGADA J, PLANELLAS J, ALLESSIE M: Mode of action of a new lass IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J. Cardiovasc. Pharmacol. (1991) 17:116-124.
42. KHAN MH: Oral dacs III antiarrhythmics: what is new? Curr. Opin. Cardiol. (2004) 19:47-51.
43. PRYSTOWSKY EN, FREELAND S, BRANYAS NA et al.: Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J. Cardiovasc. Electrophysiol. (2003) 14:S287-S290.
44. DESSERTENNE F, COUMEL P, FABIATO A: Ventricular fibrillation and torsades de pointes. Cardiovasc. Drugs Ther. (1990) 4:1177-1182.
45. CHOY AM, DARBAR D, DELL'ORTO S, RODEN DM: Exaggerated QT prolongation after cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. (1999) 34:396-401.
46. KEREN A, TZIVONI D: Torsades de pointes: prevention and therapy. Cardiovasc. Drugs Ther. (1991) 5:509-513.
47. FABER TS, ZEHENDER M, JUST H: Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf. (1994) 11:463-476.
48. STEINBERG JS, SADANIANTZ A, KRON J et al.: Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 109:1973-1980.
49. WYSE DG, WALDO AL, DI MARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
50. Na and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl. 1):S71-S78.
51. REIFFEL JA: Drug choices in the treatment of atrial fibrillation. Am. J. Cardiol. (2000) 85:12D-19D.
52. HONDEGHEM LM: Computer aided development of antiarrhythmic agents with class IIIa properties. J. Cardiovasc. Electrophysiol. (1994) 5:711-721.
53. FEDIDA D, ORTH PMR, CHEN JYC et al.: The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. (2005) 16:1227-1238.
54. DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC S, PINTER A: The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. American Heart Association, Dallas, USA (2005):AOP 53.1.
55. ANNO T, HONDEGHEM LM: Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ. Res. (1990) 66:789-803.
56. SNYDERS DJ, HONDEGHEM LM: Effects of quinidine on the sodium current of guinea pig ventricular myocytes. Evidence for a drug-associated rested state with altered kinetics. Circ. Res. (1990) 66:565-579.
57. + channels by flecainide. J. Gen. Physiol (2003) 122:365-374.
58. KONZEN G, REICHARDT B, HAUSWIRTH O: Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibres. Naunyn Schmiedebergs Arch. Pharmacol. (1990) 341:565-576.
59. NATTEL S: Atrial electrophysiology and mechanisms of atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. (2003) 8(Suppl. 1):S5-S11.
60. HUME JR, UEHARA A: Ionic basis of the different action potential configurations of single guinea-pig atrial and ventricular myocytes. J. Physiol. (Camb.) (1985) 368:525-544.
61. CAST INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. (1989) 321:406-412.
62. BARRETT TD, HAYES ES, WALKER MJ: Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias. Eur. J. Pharmacol. (1995) 285:229-238.
63. + channel current. Circ. Res. (1993) 73:210-216.
64. + current in cultured adult human atrial myocytes. Circ. Res. (1997) 80:572-579.
65. AMOS GJ, WETTWER E, METZGER F, LI Q, HIMMEL HM, RAVENS U: Differences between outward currents of human atrial and subepicardial ventricular myocytes. J. Physiol. (Lond.) (1996) 491:31-50.
66. HEIDBÜCHEL H, VEREECKE J, CARMELIET E: Three different potassium channels in human atrium: contribution to the basal potassium conductance. Circ. Res. (1990) 66:1277-1286.
67. VAN WAGONER DR: Electrophysiological remodeling in human atrial fibrillation. Pacing Clin. Electrophysiol. (2003) 26:1572-1575.
68. TRUDEAU MC, WARMKE JW, GANETZKY B, ROBERTSON GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science (1995) 269:92-95.
69. SANGUINETTI MC, TRISTANI-FIROUZI M: hERG potassium channels and cardiac arrhythmia. Nature (2006) 440:463-469.
70. Kr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des. (2006) 12:2271-2283.
71. ROBERTSON GA, JANUARY CT: HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handook Exp. Pharmacol. (2006) 171:349-355.
72. DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC A, PINTER A: Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Can. J. Cardiol. (2004) 20:198D.
73. PAUL AA, WITCHEL HJ, HANCOX JC: Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. (2002) 136:717-729.
74. HALLMAN K, CARLSSON L: Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol. Toxicol. (1995) 77:250-254.
75. WINDLE JR, GELETKA RC, MOSS AJ, ZAREBA W, ATKINS DL: Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:ΔKPQ mutation. Ann. Noninvasive Electrocardiol. (2001) 6:153-158.
76. KHAN IA, GOWDA RM: Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int. J. Cardiol. (2004) 95:1-6.
77. JU YK, SAINT DA, GAGE PW: Inactivation-resistant channels underlying the persistent sodium current in rat ventricular myocytes. Proc. Biol. Sci. (1994) 256:163-168.
78. SAINT DA, JU YK, GAGE PW: A persistent sodium current in rat ventricular myocytes. J. Physiol. (1992) 453:219-231.
79. + channels: an original mechanism of arrhythmia. Circulation (2003) 107:2233-2237.
80. + current active during repolarization. Biophys. J. (2004) 86:135a.
81. Na and suppresses early afterdepolarizations and torsades de pointes induced by lass III agents. Cardiovasc. Res. (2006) 70:486-496.
82. BEATCH GN, HELMES M, BLAAUW Y et al.: Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria - selective antiarrhythmic drug, RSD1235 in the goat. Circulation (2004) 110:III-163.
83. BEATCH GN, SHINAGAWA K, JOHNSON BD et al.: RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Pharmacologist (2002) 44(2 Suppl. 1):A15.
84. BECHARD JP, GIBSON JK, EZRIN AM: The cardiovascular effects of vernakalant in conscious Beagle dogs. Safety Pharmacology Society (2006).
85. CARLSSON I, ALMGREN O, DUKER G: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. (1990) 16:276-285.
86. EZRIN AM, GRANT SM, BELL G et al.: A dose-ranging study for RSD1235, a novel antiarrhythmic agent, in healthy volunteers. Pharmacologist (2002) 44(Suppl. 1):A15.
87. BEATCH GN, GRANTS, CLOHS L et al.: A novel atrial-selective antiarrhythmic drug, shows rapid and extensive oral absorption in man. International Society of Cardiovascular Pharmacotherapy (2003).
88. DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC S, PINTER A: A Phase II study of the investigational antiarrhythmic agent RSD1235 shows that it is atrially selective in humans. J. Cardiovasc. Pharmacol. (2007) (Submitted).
89. STIELL IG, ROWE BH, ROY D et al.: RSD1235 in the treatment of recent onset atrial fibrillation in ACT 1 (Atrial Arrhythmia Conversion Trial I) - effect of age, sex, and prior rate control medications. Ann. Emerg. Med. (2005) 46:S115.
90. PRATT C, ROY D, JUUL-MOLLER S et al.: Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a Phase III, randomized, placebo-controlled, multicenter trial. Europace (2006) 8:155-153.
91. ROY D, PRATT C, WYSE DG et al.: Efficacy and safety of RSD1235 in the treatment of recent onset atrial fibrillation in ACT1 (Atrial Arrhythmia Conversion Trial I), a Phase III, randomized, placebo-controlled, multi-center trial. European Society of Cardiology, Stockholm, Sweden (2005).
92. STIELL IG, ROY D, ROWE BH, PRATT C, DICKINSON G, KITT T: Efficacy and safety of RSD1235 in the treatment of acute atrial fibrillation. Acad. Emerg. Med. (2006) 13(Suppl. 1):S162-a.
93. CRIJNS HJ: Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs (2005) 65:1651-1667.
94. TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. (1999) 341:857-865.
95. NERBONNE JM, KASS RS: Molecular physiology of cardiac repolarization. Physiol. Rev. (2005) 85:1205-1253.